Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Drug Target
En enfermedades como la cirrosis y la diabetes, el beneficio que se obtiene de la L-Carnitina es que no permite la acumulacin de grasas
US$ 21.35
US$ 29.38
US$ 20.59
